SCHEMBL3716849

SCHEMBL3716849

COc1ccc(Cn2nc(OC)c3c(N4CCN(C(=O)OC(C)(C)C)CC4)c(C4CC4)cnc32)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.43
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ALDH1A1 P00352 3/20 0.43
TP53 P04637 3/20 0.42
KDM1A O60341 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GPR119 Q8TDV5 6/20 0.40
HTT P42858 2/20 0.40
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
CRHBP P24387 1/20 0.39
KMT2A Q03164 1/20 0.39
CRHR2 Q13324 1/20 0.39
HSD17B10 Q99714 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3723302 0.92 MAPT (0.42) MAPTLMNASMN1; SMN2ALDH1A1TP53
SCHEMBL3739575 0.91 MAPT (0.42) MAPTLMNASMN1; SMN2ALDH1A1TP53
SCHEMBL3732959 0.91 MAPT (0.41) MAPTLMNASMN1; SMN2ALDH1A1TP53
SCHEMBL3738339 0.90 MAPT (0.42) MAPTLMNASMN1; SMN2ALDH1A1TP53
SCHEMBL3717315 0.89 KDM4E (0.38) SMN1; SMN2ALDH1A1TP53KDM4EMEN1
SCHEMBL3743204 0.88 MAPT (0.39) MAPTLMNASMN1; SMN2ALDH1A1TP53
SCHEMBL3720656 0.86 CKS1B (0.44) MAPTLMNASMN1; SMN2ALDH1A1TP53
SCHEMBL3717081 0.86 MAPT (0.46) MAPTLMNASMN1; SMN2ALDH1A1TP53
SCHEMBL3729807 0.84 TDP1 (0.39) MAPTLMNASMN1; SMN2ALDH1A1TP53
SCHEMBL3729810 0.84 TDP1 (0.39) MAPTLMNASMN1; SMN2ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372842-B2 Pyrazolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2013-02-12 US disclosed
EP-2242757-B1 PYRAZOLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2012-08-01 EP disclosed
US-20100280043-A1 PYRAZOLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-11-04 US disclosed
EP-2242757-A1 PYRAZOLOPYRIDINES AS KINASE INHIBITORS Array Biopharma, Inc. (US) 2010-10-27 EP disclosed
WO-2009089359-A1 PYRAZOLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280043-A1 PYRAZOLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, BUB1B MAPT 3636/4885LMNA 1369/4885SMN1; SMN2 1288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.